Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
1.435
+0.035 (2.47%)
Nov 21, 2024, 12:08 PM EST - Market open
Salarius Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
Revenue | - | - | - | 1.84 | 5.23 | 3.47 | Upgrade
|
Revenue Growth (YoY) | - | - | - | -64.84% | 51.03% | 77.57% | Upgrade
|
Cost of Revenue | - | - | - | 8.55 | 6.91 | 4.02 | Upgrade
|
Gross Profit | - | - | - | -6.71 | -1.68 | -0.55 | Upgrade
|
Selling, General & Admin | 5.19 | 5.72 | 7.14 | 6.1 | 6.11 | 7.71 | Upgrade
|
Research & Development | 1.55 | 7.17 | 15.84 | - | - | - | Upgrade
|
Operating Expenses | 6.74 | 12.89 | 22.98 | 6.1 | 6.11 | 7.71 | Upgrade
|
Operating Income | -6.74 | -12.89 | -22.98 | -12.81 | -7.79 | -8.27 | Upgrade
|
Interest & Investment Income | 0.28 | 0.35 | 0.22 | - | - | 0.02 | Upgrade
|
Other Non Operating Income (Expenses) | - | - | 0.01 | 0.04 | 0.43 | 1.31 | Upgrade
|
EBT Excluding Unusual Items | -6.46 | -12.54 | -22.74 | -12.77 | -7.35 | -6.94 | Upgrade
|
Impairment of Goodwill | - | - | -8.87 | - | - | - | Upgrade
|
Pretax Income | -6.46 | -12.54 | -31.61 | -12.77 | -7.35 | -6.94 | Upgrade
|
Net Income | -6.46 | -12.54 | -31.61 | -12.77 | -7.35 | -6.94 | Upgrade
|
Preferred Dividends & Other Adjustments | - | - | - | - | 0.4 | - | Upgrade
|
Net Income to Common | -6.46 | -12.54 | -31.61 | -12.77 | -7.75 | -6.94 | Upgrade
|
Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Shares Change (YoY) | 69.10% | 53.66% | 28.40% | 165.53% | 376.61% | - | Upgrade
|
EPS (Basic) | -12.42 | -30.74 | -119.02 | -61.73 | -99.48 | -424.42 | Upgrade
|
EPS (Diluted) | -12.42 | -30.74 | -119.02 | -61.73 | -100.00 | -424.42 | Upgrade
|
Free Cash Flow | -7.69 | -12.85 | -17.6 | -10.2 | -10.31 | -11.58 | Upgrade
|
Free Cash Flow Per Share | -14.77 | -31.48 | -66.26 | -49.32 | -132.41 | -708.57 | Upgrade
|
Gross Margin | - | - | - | - | -32.11% | -15.99% | Upgrade
|
Operating Margin | - | - | - | -696.27% | -148.78% | -238.53% | Upgrade
|
Profit Margin | - | - | - | -693.84% | -148.06% | -200.18% | Upgrade
|
Free Cash Flow Margin | - | - | - | -554.29% | -197.08% | -334.20% | Upgrade
|
EBITDA | -6.73 | -12.88 | -22.97 | -12.79 | -7.77 | -8.25 | Upgrade
|
EBITDA Margin | - | - | - | - | -148.44% | -238.02% | Upgrade
|
D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | Upgrade
|
EBIT | -6.74 | -12.89 | -22.98 | -12.81 | -7.79 | -8.27 | Upgrade
|
EBIT Margin | - | - | - | - | -148.78% | -238.53% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.